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Prognostic factors are associated with 
the risk of future health outcomes in 
individuals with a particular health 
condition or some clinical start point 
(eg, a particular diagnosis). Research 
to identify genuine prognostic factors is 
important because these factors can 
help improve risk stratification, 
treatment, and lifestyle decisions, and 
the design of randomised trials. 
Although thousands of prognostic 
factor studies are published each year, 
often they are of variable quality and 
the findings are inconsistent. 
Systematic reviews and meta-analyses 
are therefore needed that summarise 
the evidence about the prognostic 
value of particular factors. In this 
article, the key steps involved in this 
review process are described.
Systematic reviews and meta-analyses are common 
in the medical literature, routinely appearing in 
specialist and general medical journals, and forming 
the cornerstone of Cochrane. The majority of systematic 
reviews focus on summarising the benefit of one or more 
therapeutic interventions for a particular condition. 
However, they are also important for summarising 
other evidence, such as the accuracy of screening and 
diagnostic tests,1 the causal association of risk factors 
for disease onset, and the prognostic ability of bespoke 
factors and biomarkers. Prognostic evidence arises from 
prognosis studies, which aim to examine and predict 
future outcomes (such as death, disease progression, 
side effects or medical complications like pre-eclampsia) 
in people with a particular health condition or start point 
(such as those developing a certain disease, undergoing 
surgery, or women who are pregnant).
The PROGRESS (PROGnosis RESearch Strategy) 
framework defines four types of prognosis research 
objectives: (a) to summarise overall prognosis (eg, 
overall risk or rate) of health outcomes for groups with a 
particular health condition2; (b) to identify prognostic 
factors associated with changes in health outcomes3; 
(c) to develop, validate, and examine the impact of 
prognostic models for individualised prediction of 
such outcomes4; and (d) to identify predictors of an 
individual’s response to treatment.5 Each objective 
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Summary pointS
•   Primary studies to identify prognostic factors are abundant, but often findings are inconsistent and quality is variable. Systematic 
reviews and meta-analyses are urgently needed to identify, evaluate, and summarise prognostic factor studies and their findings.
•   A clear review question should be defined using the PICOTS system (Population, Index prognostic factor, Comparator prognostic factors, 
Outcome, Timing, Setting), and a transparent search undertaken for eligible articles. Broad search strings may be required, leading to a 
large number of articles to screen.
•   A data extraction phase is needed to obtain the relevant information from each study. A modification of CHARMS (checklist for critical 
appraisal and data extraction for systematic reviews of prediction modelling studies) can be used for prognostic factors (CHARMS-PF).
•   The QUIPS tool (quality in prognostic factor studies) can be used to examine each study’s risk of bias. Unfortunately, many primary 
studies may have a high risk of bias because of poor design standards, conduct, and analysis. Applicability of a study should also be 
checked.
•   If appropriate, meta-analysis can be used to combine prognostic effect estimates (such as hazard ratios, risk ratios, or odds ratios) 
across studies to produce an overall summary of a factor’s prognostic effect. Between-study heterogeneity should be expected and 
accounted for.
•   Ideally separate meta-analyses should be performed for unadjusted and adjusted prognostic effect estimates; adjusted estimates are 
important to examine a factor’s independent prognostic value over and above (that is, after adjustment for) other prognostic factors.
•   Separate meta-analyses may also be required for each method of measurement (for factors and outcomes), each approach to handling 
continuous factors, and each type of estimate (such as hazard ratios or odds ratios).
•   Publication bias is a major threat to the validity of meta-analyses of prognostic factor studies based on published evidence, and may 
cause small-study effects (asymmetry on a funnel plot).
•   REMARK (reporting recommendations for tumour marker prognostic studies) and PRISMA (preferred reporting items for systematic 
reviews and meta-analyses) can be used to guide the reporting of the systematic review and meta-analysis of prognostic factor studies; 
the degree of confidence in the summary results from the review may be examined by use of adapted forms of GRADE (grades of 
recommendation, assessment, development, and evaluation) for interventions and diagnostic test accuracy studies.
•   Availability of individual participant data from primary prognostic factor studies may alleviate many of the challenges.
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requires specific methods and tools for conducting 
a systematic review and meta-analysis. Two recent 
articles provided a guide to undertaking reviews and 
meta-analysis of prognostic (prediction) models.6 7 In 
this article, we focus on prognostic factors. 
A prognostic factor is any variable that is associated 
with the risk of a subsequent health outcome 
among people with a particular health condition. 
Different values or categories of a prognostic factor 
are associated with a better or worse prognosis 
of future health outcomes. For example, in many 
cancers, tumour grade at the time of histological 
examination is a prognostic factor because it is 
associated with time to disease recurrence or death. 
Each grade represents a group of patients with a 
different prognosis, and the risk or rate (hazard) of the 
outcome increases with higher grades. Many routinely 
collected patient characteristics are prognostic, 
such as sex, age, body mass index, smoking status, 
blood pressure, comorbidities, and symptoms. Many 
researched prognostic factors are biomarkers, which 
include a diverse range of blood, urine, imaging, 
electrophysiological, and physiological variables.
Prognostic factors have many potential uses, 
including aiding treatment and lifestyle decisions, 
improving individual risk prediction, providing novel 
targets for new treatment, and enhancing the design 
and analysis of randomised trials.3 This motivates 
so-called “prognostic factor research” to identify 
genuine prognostic factors (sometimes also called 
“predictor finding studies”8).9 Although thousands of 
such studies are published each year, often they are 
of variable quality and have inconsistent findings. 
Systematic reviews and meta-analyses are therefore 
urgently needed to summarise the evidence about 
the prognostic value of particular factors.10-12 In this 
article, we provide a step-by-step guide on conducting 
such reviews. Our aim is to help readers, healthcare 
providers, and researchers understand the key 
principles, methods, and challenges of reviews of 
prognostic factor studies.
Step 1: Defining the review question
The first step is to define the review question. A 
review of prognostic factor studies falls within the 
second objective of the PROGRESS framework2 
because it aims to summarise the prognostic value 
of a particular factor (or each of multiple factors) for 
relevant health outcomes and time points in people 
with a specific health condition (eg, disease). Some 
reviews are broad; for example, Riley and colleagues 
aimed to identify any prognostic factor for overall and 
disease free survival in children with neuroblastoma 
or Ewing’s sarcoma.13 Other reviews have a narrower 
focus; for example, Hemingway and colleagues aimed 
to summarise the evidence on whether C reactive 
protein (CRP) is a prognostic factor for fatal and non-
fatal events in patients with stable coronary disease.14 
This CRP review is used as an example throughout this 
article.
CHARMS (checklist for critical appraisal and 
data extraction for systematic reviews of prediction 
modelling studies) provides guidance for formulating 
a review question (table 1 in the article by Moons and 
colleagues15). Although CHARMS was developed15 
and refined6 for reviews of prediction model studies, 
it can also be used to define and frame the question 
for reviews of prognostic factor studies. CHARMS15 and 
subsequent improvements6 propose a modification 
of the traditional PICO system (Population, Index 
intervention, Comparison and Outcome) used in 
systematic reviews of therapeutic intervention studies.
The modification is called PICOTS, because it also 
considers Timing and Setting (box 1). In the context 
of prognostic factor reviews, the “P” of population 
and the “O” of outcome remain largely the same as in 
the original PICO system, but the “I” refers to index 
prognostic factors and the “C” refers to other prognostic 
factors that can be considered as comparators in some 
way. For example, the aim may be to compare the 
prognostic ability of a certain index factor with one 
or more other (that is, comparator) prognostic factors; 
or to investigate the adjusted prognostic value of a 
particular index factor over and above (adjusted for) 
other (that is, comparator) prognostic factors. If the 
only aim is to summarise the unadjusted prognostic 
effect of a particular index factor, which is not 
generally recommended, then no comparator factor is 
being considered. The “T” denotes timing and refers 
to two concepts of time. Firstly, at what time point the 
prognostic factors under review are to be measured or 
assessed (that is, the time point at which prognosis 
information is required); and secondly, over what time 
period the outcomes are predicted by these factors. The 
“S” of setting refers to the setting or context in which 
the index prognostic factors are to be used because 
the prognostic ability of a factor may change across 
healthcare settings.
An important component of reviews of prognostic 
factors is whether unadjusted or adjusted estimates 
of the index prognostic factors will be summarised, or 
both. We recommend that reviewers primarily focus 
on adjusted prognostic factor estimates because they 
reveal whether a certain index factor contributes 
independently to the prediction of the outcome over and 
above (that is, after adjustment for) other prognostic 
factors. In particular, for each clinical scenario there 
are often so-called “established” or “conventional” 
prognostic factors that are always measured. 
Therefore, for prognostic factors under review, it is 
important to understand whether they contribute 
additional (sometimes called “independent”) 
prognostic information to the routinely measured 
ones. This means that reviewers need adjusted (and 
not unadjusted or crude) prognostic effect estimates 
to be estimated and reported in primary prognostic 
factor studies. Such adjusted prognostic estimates 
are typically derived from a multivariable regression 
model containing the established prognostic factors 
plus each index prognostic factor of interest. 
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For example, consider a logistic regression of a 
binary outcome including three adjustment factors (A1, 
A2, and A3) and one new index prognostic factor (X1), 
which is expressed as: 
ln(p/(1−p)) = α+β1A1+β2A2+β3A3+β4X1
Here, “p” is the probability of the outcome. After 
estimation of all the unknown parameters (that is, α, 
β1, β2, β3, β4), of key interest is the estimated β4. This 
parameter provides the adjusted prognostic effect of 
the index prognostic factor and reveals its independent 
contribution to the prediction of the outcome over and 
above the prognostic effects of the other (established 
comparator) factors A1, A2, and A3 combined.
The need to focus on adjusted prognostic effects is 
no different from (systematic reviews of) aetiological 
studies, in which the focus is on estimating the 
association of a certain causal risk factor after 
adjustment for other risk factors. In such causal 
research, these factors are usually referred to as 
“confounders” rather than as “other prognostic 
Table 1 | CHARMS-PF checklist of key items to be extracted from primary studies of prognostic factors, based on additions and modifications of the 
original CHARMS checklist for primary studies of prediction models15
Domain and key items General Applicability Risk of bias
Source of data:
 Source of data (eg, cohort, case control, randomised trial, or registry data) X X X
Participants:
  Participant eligibility and recruitment method (eg, consecutive participants, location, number of centres, setting, inclusion and 
exclusion criteria)
X X X
 Participant description X X
 Details of treatments received (if relevant) X X
 Study dates X X
Outcomes to be predicted:
 Definition and method for measurement of outcomes X X
 Was the same outcome definition (and method for measurement) used in all participants? X
 Types of outcomes (eg, single or combined endpoints)? X X
 Were the outcomes assessed without knowledge of the candidate prognostic factors (that is, blinded)? X
 Were candidate prognostic factors part of the outcome (eg, when using a panel or consensus outcome measurement)? X
 Time of outcome occurrence or summary of duration of follow-up X X X
Prognostic factors (index and comparator prognostic factors):
  Number and type of prognostic factors (eg, obtained from demographics, patient history, physical examination, additional testing, 
disease characteristics)
X X 
 Definition and method for measurement of prognostic factors X X
 Timing of prognostic factor measurement (eg, at patient presentation, diagnosis, treatment initiation, at the end of surgery) X X
 Were prognostic factors assessed blinded for outcome, and for each other (if relevant)? X
 Handling of prognostic factors in the analysis (eg, continuous, linear, non-linear transformations or categorised) X
Sample size:
 Was a sample size calculation conducted and, if so, how? X
 Number of participants and number of outcomes or events X
 Number of outcomes or events in relation to the number of candidate prognostic factors (events per variable) X
Missing data:
 Number of participants with any missing value (in the prognostic factors and outcomes) X X
 Number of participants with missing data for each prognostic factor of interest X
  Details of attrition (loss to follow-up) and, for time-to-event outcomes, number of censored observations (ideally in each category 
for those categorical prognostic factors of interest)
X
 Handling of missing data (eg, complete case analysis, imputation, or other methods) X
Analysis:
 Modelling method (eg, linear, logistic, Cox, parametric survival, competing risks) regression) X X
  How modelling assumptions were checked; in particular, for time-to-event outcomes and the analysis of hazard ratios, the method 
for assessing non-proportional hazards (non-constant hazard ratios over time)
X
  Method for selection of prognostic factors for inclusion in multivariable modelling (eg, all candidate prognostic factors considered, 
preselection of established prognostic factors, retain only those significant from univariable analysis)
X
  Method for selection or exclusion of prognostic factors (including those of interest and those used as adjustment factors) during 
multivariable modelling (eg, backward or forward selection, or full model approach including all factors regardless), and criteria 
used for any selection or exclusion (eg, P value, Akaike information criterion)
X
  Method of handling each continuous prognostic factor (eg, dichotomisation, categorisation, linear, non-linear), including values 
of any cutpoints used and their justification; for non-linear trends, the method of identifying non-linear relationships (eg, splines, 
fractional polynomials)
X
Results:
  Unadjusted and adjusted prognostic effect estimates (eg, risk ratios, odds ratios, hazard ratios, mean differences) for each prog-
nostic factor of interest, and the corresponding 95% confidence interval (or variance or standard error). Details of any non-linear 
relationships and whether modelling assumptions hold; in particular, for time-to-event outcomes, any evidence of non-proportional 
hazards (non-constant hazard ratios) for each prognostic factor of interest
X X X
 For each extracted adjusted prognostic effect estimate of interest, the set of adjustment factors used X X X 
Interpretation and discussion:
 Interpretation of presented results X X
 Comparison with other studies, discussion of generalisability, strengths and limitations X X
CHARMS=checklist for critical appraisal and data extraction for systematic reviews of prediction modelling studies. CHARMS-PF enables reviewers to describe, assess (eg, for applicability or risk of 
bias), and summarise (individually and within a meta-analysis) primary studies.
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factors,” which is the term typically used for prognosis 
research. The crude (unadjusted) prognostic effect of 
some index factors may completely disappear after 
adjustment and is therefore rather uninformative, 
especially because prognostication in healthcare is 
rarely based on a single prognostic factor but rather on 
the information from multiple prognostic factors.4
This article focuses on systematic reviews to 
summarise prognostic factor effect estimates. 
Some primary studies may also evaluate an index 
factor’s added value in terms of improvement in risk 
classification and clinical use (eg, measures such as 
net reclassification improvement and net benefit), 
and change in prediction model performance (eg, by 
calculating the change in the concordance index, also 
known as the C statistic or area under the receiver 
operating characteristics (ROC) curve).17-20 However, 
this is beyond the scope of this article, and we refer the 
reader to other relevant sources.6 21 22
Application to CRP review
CRP is widely studied for its prognostic value in 
patients with coronary disease. However, there is 
uncertainty whether CRP is useful because US and 
European clinical practice guidelines recommend 
measurement but clinical practice varies widely. 
This uncertainty motivated the systematic review by 
Hemingway and colleagues,14 with the corresponding 
PICOTS system presented in box 1. No studies were 
excluded on the basis of methodological standards, 
sample size, duration of follow-up, publication year, or 
language of publication.
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Fig 1 | Forest plot showing the study specific estimates and meta-analysis summary 
result of the adjusted prognostic effect (risk ratio) of C reactive protein taken from 
the review of Hemingway and colleagues14; all studies were adjusted for a core set of 
existing prognostic factors (age, sex, smoking status, diabetes, obesity, and lipids), 
plus up to 14 other prognostic factors. Meta-analysis results shown are based on 
a random effects meta-analysis model with DerSimonian and Laird estimation of 
the between-study variances. The summary result is identical to Hemingway and 
colleagues,14 but the confidence interval is wider because we used the Hartung-Knapp 
approach to account for uncertainty in variance estimates.16 Although “risk ratio” is 
used, the estimates actually correspond to a mixture of risk ratios, odds ratios, and 
hazard ratios
Box 1: Six items (PICOTS) defining the question for systematic reviews of prognostic factor studies, based on CHARMS (checklist for critical 
appraisal and data extraction for systematic reviews of prediction modelling studies)6 15 and applied to a review of the adjusted prognostic 
value of C reactive protein (CRP)14
• Population: define the target population for which prognostic factors under review are to be used. For example, CRP review: patients with stable 
coronary disease, defined as clinically diagnosed angina pectoris or angiographic disease, or a history of acute coronary syndrome at least two 
weeks before prognostic factor (CRP) measurement.
• Index prognostic factor: define the factors for which prognostic value is under review. For example, CRP review: CRP was the single biomarker 
reviewed for its prognostic value.
• Comparator prognostic factors: comparator prognostic factors can be considered in a review in various ways. For example, the aim could be to 
compare the prognostic ability of a certain index factor with two or more other (that is, comparator) prognostic factors; or to review the adjusted 
prognostic value of a particular index factor—that is, over and above (adjusted for, independent of) other existing (that is, comparator) prognostic 
factors. If the only aim is to summarise the unadjusted prognostic effect of a particular index factor, then no comparator factor is being considered. 
For example, CRP review: the focus was on the adjusted prognostic value of CRP—that is, its prognostic effect after adjusting for existing (comparator) 
prognostic factors. In particular, adjustment for the following conventional prognostic factors was of interest: age, sex, smoking status, obesity, 
diabetes, and one or more lipid variables (from total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, 
triglycerides) and inflammatory markers (fibrinogen, interleukin 6, white cell count).
• Outcome: define the outcomes for which the prognostic ability of the factor(s) under review are of interest. For example, CRP review: outcome events 
were defined as coronary (coronary death, sudden cardiac death, acute non-fatal myocardial infarction, primary percutaneous coronary intervention, 
unplanned emergency admissions with unstable angina), cardiovascular (when coronary events were reported in combination with heart failure, 
stroke, or peripheral arterial disease), and all cause mortality.
• Timing: define firstly at what time points the prognostic factors (index and comparators) are to be used (that is, the time point of prognostication), 
and secondly over what time period the outcomes are predicted by these factors. For example, CRP review: the CRP measurement had to be done at 
least two weeks after diagnosis and all follow-up information on the outcomes (all time periods) was extracted from the studies.
• Setting: define the intended setting and role of the prognostic factors under review. For example, CRP review: CRP measurement was studied in 
primary and secondary care to provide prognostic information about patients diagnosed with coronary heart disease; this information may be useful 
for healthcare professionals treating and managing such patients.
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Step 2: Searching for and selection of eligible studies
The next step is to identify primary studies that are 
eligible for review; studies that address the review 
question defined in step 1 following the PICOTS 
framework. Unfortunately, it is more difficult to identify 
prognostic factor studies than randomised trials of 
interventions. Prognosis studies do not tend to be 
indexed (“tagged”) because a taxonomy of prognosis 
research is not widely recognised. Moreover, compared 
with studies of interventions, there is much more 
variation in the design of prognostic factor studies (eg, 
data from cohort studies, randomised trials, routine 
care registries, and case-control studies can all be 
used), patient inclusion criteria, prognostic factor and 
outcome measurement, follow-up time, methods of 
statistical analysis, and adjustment of (and number of) 
other prognostic factors (covariates). Between-study 
heterogeneity is therefore the rule rather than the 
exception in prognostic factor research. It is essential 
that systematic reviews of prognostic factor studies 
define the study inclusion and exclusion criteria 
based on the PICOTS structure (step 1) because this 
determines the study search and selection strategy.
Typically, broad search and selection filters are 
required that combine terms related to prognosis 
research (such as prognostic, predict, predictor, factor, 
independent) with domain or disease specific terms 
(such as the name of prognostic factors and the targeted 
disease or patient population).23 A broad search comes 
at the (often considerable) expense of retrieving many 
irrelevant records. Geersing and colleagues24 validated 
various existing search strategies for prognosis studies 
and suggested a generic filter for identifying studies of 
prognostic factors,23 25 26 which extended the work of 
Ingui, Haynes, and Wong.23 25 26 When tested in a single 
review of prognostic factors, this generic filter had a 
number needed to read of 569 to identify one relevant 
article, emphasising the difficulty in targeting prognostic 
factor articles. The number needed to read could be 
considerably reduced when specific factors or populations 
are added to the filter. Even then, care is needed to be 
inclusive because multiple terms are often used for the 
same meaning; for example, biomarker MYCN is also 
referred to as n-myc and nmyc, among other terms.13
Once the search is complete, each potentially 
relevant study must be screened for its applicability to 
the review question. Because of the heterogeneity in 
prognostic factor studies, during this study selection 
phase more deviations from the defined PICOTS (in 
step 1) are possible (far greater than what is typically 
encountered during the selection of randomised 
intervention studies). The applicability of this primary 
study selection should firstly be based on title and 
abstract screening, followed by full text screening, 
both ideally done by two researchers independently. 
Any discrepancies should be resolved through 
discussion, potentially with a third reviewer. To check 
if any relevant articles have been missed, it is helpful to 
share the list of identified articles with researchers in 
the field to examine the reference lists of these articles 
and to perform a citation search.
Application to CRP review
Hemingway and colleagues included any prospective 
observational study that reported risk of subsequent 
events among patients with stable coronary disease 
in relation to measured CRP values.14 Eligible studies 
had to include patients with stable coronary disease, 
defined as clinically diagnosed angina pectoris or 
angiographic disease, or a history of previous acute 
coronary syndrome at least 2 weeks before CRP 
measurement. Hemingway and colleagues searched 
MEDLINE between 1966 and 25 November 2009 and 
EMBASE between 1980 and 17 December 2009, using 
a search string containing terms for coronary disease, 
prognostic studies, and CRP. The search identified 
1566 articles, of which 83 fulfilled the inclusion 
criteria. If specific terms for CRP had not been included 
in the search string, then the total number of identified 
articles would have far exceeded 1566.
Step 3: Data extraction
The next step is to extract key information from each 
selected study. Data extraction provides the necessary 
data from each study, which enables reviewers to 
examine their (eventual) applicability to the review 
question and their risk of bias (see step 4). This step 
also provides the information required for subsequent 
qualitative and quantitative (meta-analysis) synthesis 
of the evidence across studies. The CHARMS checklist 
gives explicit guidance (table 2 in the article by Moons 
and colleagues15) about which key items across 11 
domains should be extracted from primary studies 
of prediction models, and for what reason (that is, 
to provide general information about the primary 
study, to guide risk of bias assessment, or to assess 
applicability of the primary study to the review 
question). Based on our experience of conducting 
systematic reviews of prognostic factor studies, we 
modified the original CHARMS checklist for prediction 
model studies to make it suitable for data extraction 
in reviews of prognostic factors (here referred to as 
CHARMS-PF; table 1). This basically means that three 
domains typically addressing multivariable prediction 
modelling aspects were combined to one overall 
analysis domain, while other domain names and key 
items were slightly reworded or extended. Reasons for 
extraction of each key item are similar to CHARMS for 
prediction models. Because we developed the original 
CHARMS checklist, a wider consensus of the CHARMS-
PF content was not considered necessary.
Reviewers should extract fundamental information 
from the primary prognostic factor studies, such as the 
dates, setting, study design, definitions of start points, 
outcomes, follow-up length, and prognostic factors; 
reviewers will often find large heterogeneity in this 
information across studies. The extracted information 
can be summarised in tables of study characteristics. 
In addition, more specific information is needed to 
properly assess applicability and risk of bias (see step 
4), such as methods used to measure prognostic factors 
and outcomes, handling missing data, attrition (loss to 
follow-up), and whether estimated associations of the 
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prognostic factors under review were adjusted for other 
prognostic factors. This information also enhances the 
potential for meta-analysis and the presentation and 
interpretation of subsequent summary results (see 
steps 5-8).
To enable meta-analysis of prognostic factor 
studies, the key elements to extract are estimates, 
and corresponding standard errors or confidence 
intervals, of the prognostic effect for each factor 
of interest; for example, the estimated risk ratio or 
odds ratio (for binary outcomes), hazard ratio (for 
time-to-event outcomes), or mean difference (for 
continuous outcomes). As most prognostic factor 
studies consider time-to-event outcomes (including 
censored observations and different follow-up lengths 
for patients), hazard ratios are often the most suitable 
effect measure. A concern is that hazard ratios may not 
be constant over time, and therefore any evaluations 
of non-proportional hazards (that is, non-constant 
hazard ratios for the prognostic factors of interest) 
should also be extracted; however, such information is 
rarely reported in sufficient detail.
Unfortunately, many prognostic factor studies do 
not adequately report estimated prognostic effect 
measures or their precision. For this reason, methods 
are available to restore the missing information upon 
data extraction. In particular, Parmar and colleagues28 
and Tierney and colleagues29 describe how to obtain 
unadjusted hazard ratio estimates (and their variances) 
when they are not reported directly. For example, 
under assumptions, the number of outcomes (events) 
and an available P value (eg, from a log rank test or 
Cox regression) can be used to indirectly estimate the 
unadjusted hazard ratio between two groups defined 
by a particular factor (eg, “high” versus “normal” 
levels). Perneger and colleagues30 report how to derive 
unadjusted hazard ratios from survival proportions, 
and Pérez and colleagues suggest using a simulation 
approach.31 Even with such indirect estimation 
methods, not all results can be obtained. For example, 
in a systematic review of 575 studies investigating 
prognostic factors in neuroblastoma,32 the methods of 
Parmar and colleagues were used to obtain 204 hazard 
ratio estimates and their confidence intervals; but this 
represented only 35.5% of the potential evidence.
Although indirect estimation methods help retrieve 
unadjusted prognostic factor effect estimates, they 
often have limited value for obtaining adjusted effect 
Table 2 | QUIPS tool (quality in prognostic factor studies), which can be used to classify risk of bias of prognostic factor studies
Domains Signalling items Risk of bias ratings
1. Study participation (a) Adequate participation in the study by eligible persons 
(b) Description of the target population or population of interest 
(c) Description of the baseline study sample 
(d) Adequate description of the sampling frame and recruitment 
(e) Adequate description of the period and place of recruitment 
(f) Adequate description of inclusion and exclusion criteria
High: the relationship between the PF and outcome is very likely to be 
different for participants and eligible non-participants 
Moderate: the relationship between the PF and outcome may be 
different for participants and eligible non-participants 
Low: the relationship between the PF and outcome is unlikely to be 
different for participants and eligible non-participants
2. Study attrition (a) Adequate response rate for study participants 
(b) Description of attempts to collect information on participants who 
dropped out 
(c) Reasons for loss to follow-up are provided 
(d) Adequate description of participants lost to follow-up 
(e) There are no important differences between participants who completed 
the study and those who did not
High: the relationship between the PF and outcome is very likely to be 
different for completing and non-completing participants 
Moderate: the relationship between the PF and outcome may be 
different for completing and non-completing participants 
Low: the relationship between the PF and outcome is unlikely to be 
different for completing and non-completing participants
3.  Prognostic factor 
 measurement
(a) A clear definition or description of the PF is provided 
(b) Method of PF measurement is adequately valid and reliable 
(c) Continuous variables are reported or appropriate cutpoints are used 
(d) The method and setting of measurement of PF is the same for all study 
participants 
(e) Adequate proportion of the study sample has complete data for the PF 
(f) Appropriate methods of imputation are used for missing PF data
High: the measurement of the PF is very likely to be different for 
 different levels of the outcome of interest 
Moderate: the measurement of the PF may be different for different 
levels of the outcome of interest 
Low: the measurement of the PF is unlikely to be different for different 
levels of the outcome of interest
4.  Outcome  measurement (a) A clear definition of the outcome is provided 
(b) Method of outcome measurement used is adequately valid and reliable 
(c) The method and setting of outcome measurement is the same for all 
study participants
High: the measurement of the outcome is very likely to be different 
related to the baseline level of the PF 
Moderate: the measurement of the outcome may be different related 
to the baseline level of the PF 
Low: the measurement of the outcome is unlikely to be different 
 related to the baseline level of the PF
5.  Adjustment for other 
prognostic factors
(a) All other important PFs are measured 
(b) Clear definitions of the important PFs measured are provided 
(c) Measurement of all important PFs is adequately valid and reliable 
(d) The method and setting of PF measurement are the same for all study 
participants 
(e) Appropriate methods are used to deal with missing values of PFs, such 
as multiple imputation 
(f) Important PFs are accounted for in the study design 
(g) Important PFs are accounted for in the analysis
High: the observed effect of the PF on the outcome is very likely to be 
distorted by another factor related to PF and outcome 
Moderate: the observed effect of the PF on outcome may be distorted 
by another factor related to PF and outcome 
Low: the observed effect of the PF on outcome is unlikely to be 
 distorted by another factor related to PF and outcome
6.  Statistical analysis and 
reporting
(a) Sufficient presentation of data to assess the adequacy of the analytic 
strategy 
(b) Strategy for model building is appropriate and is based on a conceptual 
framework or model 
(c) The selected statistical model is adequate for the design of the study 
(d) There is no selective reporting of results
High: the reported results are very likely to be spurious or biased 
related to analysis or reporting 
Moderate: the reported results may be spurious or biased related to 
analysis or reporting 
Low: the reported results are unlikely to be spurious or biased related 
to analysis or reporting
PF=prognostic factor. Some wording from Hayden and colleagues27 has been modified to be consistent with the terminology used in this article.
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estimates. Furthermore, even when multiple studies 
provide the adjusted prognostic effect of a particular 
factor, the set of adjustment factors will usually differ 
across studies, which complicates the interpretation of 
subsequent meta-analysis results. We recommend that 
reviewers predefine the core set of prognostic factors for 
the outcome of interest (eg, age, sex, smoking status, 
disease stage) that represents the desired “minimal” 
set of adjustment factors. An agreed process among 
health professionals and researchers in the field could 
be required to define this set. For example, a list of 
established prognostic factors could be identified that 
are routinely used within current prognostication of 
the clinical population of interest.
It may also be necessary to standardise the extracted 
estimates to ensure they all relate to the same scale and 
direction in each study. In particular, the direction of the 
prognostic effect will need standardising if one study 
compares the hazard rate in a factor’s “high” versus 
“normal” group, whereas another study compares 
the hazard rate in the factor’s “normal” versus “high” 
group. When the outcome is defined differently across 
studies, approaches to convert effect measures on 
different outcome scales could be useful.33 Also, to deal 
with different cutpoint levels for values of a particular 
factor,34 the prognostic effects of “high” versus 
“normal” could be converted to prognostic effects 
relating to a 1 unit increase in the factor. This requires 
assumptions about the underlying distribution of the 
factor. Such an approach was used by Hemingway and 
colleagues.14 Of concern, however, is that the actual 
distribution of a prognostic factor may be unknown (or 
even vary across studies). Finally, it is also possible to 
derive standardised effect estimates by standardising 
the corresponding regression coefficients.35
Application to CRP review
Hemingway and colleagues extracted background 
information such as year of study start, number of 
included patients, mean age, baseline coronary morbidity 
(eg, proportion with stable angina), average levels of 
biomarker at baseline, method of CRP measurement, 
follow-up duration, and number and type of events. Basic 
information was often missing. For example, nearly a fifth 
of studies did not report the method of measurement, and 
only a quarter gave the number of patients included in 
the analyses and reasons for dropout. Prognostic effect 
estimates for CRP were extracted in terms of the reported 
risk ratio, odds ratio, or hazard ratio (labelled generally 
as “risk ratio” in this article), and 95% confidence 
intervals. These effect estimates were then converted to a 
standardised scale comparing the highest third with the 
lowest third of the (log transformed) CRP distribution. 
If available, separate prognostic effect estimates were 
extracted for different degrees of adjustment for other 
prognostic factors.
Step 4: Evaluating applicability and risk of bias of 
primary studies
Once eligible studies are identified and data are 
extracted, an important next step is to assess the 
applicability and risk of bias (quality) of each study in 
the review. As for steps 2 and 3, ideally this is done by 
two reviewers, independently, with any discrepancies 
resolved. Applicability refers to the extent to which a 
selected study (in step 2) matches the review question 
in terms of the population, timing, prognostic factors, 
and outcomes (endpoints) of interest. Just because 
a study is eligible for inclusion does not mean it is 
free from applicability concerns. Some aspects of a 
study may be applicable (eg, correct condition at start 
point, with prognostic factors of interest evaluated) 
but not others (eg, incorrect population or setting, 
inappropriate outcome definition, different follow-up 
time, lack of adjustment for conventional prognostic 
factors). Applicability is typically first assessed during 
title and abstract screening, and then during this step, 
so that it is based on full text screening and determined 
by PICOTS (step 1) and inclusion and exclusion criteria 
of studies (step 2).
Risk of bias refers to the extent to which flaws in the 
study design or analysis methods could lead to bias in 
estimates of the prognostic factor effects. Unfortunately, 
based on growing empirical evidence from systematic 
reviews examining methodology quality, many primary 
studies will be at high risk of bias.8 32 36-44 For prognostic 
factor studies, Hayden and colleagues developed the 
QUIPS checklist (quality in prognostic factor studies) 
for examining risk of bias across six domains27: 
study participation, study attrition, prognostic factor 
measurement, outcome measurement, adjustment for 
other prognostic factors, and statistical analysis and 
reporting. Table 2 shows the signalling items within 
these domains to help guide reviewers in making low, 
unclear, or high risk of bias classifications. Additional 
guidance may be found in general tools examining the 
quality of observational studies,45 46 and the REMARK 
guideline (reporting recommendations for tumour 
marker prognostic studies) for reporting of primary 
prognostic factor studies.47 48
We recommend that users first operationalise 
criteria to assess the signalling items and domains 
for the specific review question. For example, with 
the study participation and attrition domains, 
this includes defining a priori the most important 
characteristics that could indicate a systematic bias 
in study recruitment (study participation domain) and 
loss to follow-up (study attrition domain). Defining 
these characteristics ahead of time will facilitate 
assessment and consensus related to the importance of 
potential differences that could influence the observed 
association between the index prognostic factors and 
outcomes of interest. Definitions of sufficiently valid 
and reliable measurement of the index prognostic 
factors and outcomes should also be specified at 
the protocol stage. Similarly, the core set of other 
(adjustment) prognostic factors that are deemed 
necessary for the primary studies to have adjusted for, 
should be predefined to facilitate judgment related to 
risk of bias in domain 5.
Overall assessment of the six risk of bias domains is 
undertaken by considering the risk of bias information 
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from the signalling items for each domain, rated as 
low, moderate, and high risk of bias. Occasionally, item 
information needed to assess the bias domains is not 
available in the study report. When this occurs, other 
publications that may have used the same dataset 
(which often occurs in prognostic studies based on 
large existing cohorts) should be consulted and study 
authors should be contacted for additional information. 
An informed judgment about the potential risk of bias 
for each bias domain should be made independently 
by two reviewers, and discussed to reach consensus. 
Each of the six domains needs to be rated and reported 
separately because this will inform readers, flag 
improvements needed for subsequent primary studies, 
and facilitate future meta-epidemiological research. 
We recommend defining studies with an overall “low 
risk of bias” as those studies where all, or the most 
important domains (as determined a priori), are rated 
as having low (or low to moderate) risk of bias.
Application to CRP review
Hemingway and colleagues assessed the quality of 
included studies by the quality of their reporting 
on 17 items derived from the REMARK guideline.48 
The median number of study quality items reported 
was seven of a possible 17, and standards did not 
change between 1997 and 2009. Only two studies 
referred to a study protocol, with none referring to a 
statistical analysis plan. Hemingway and colleagues 
noted that this “makes it difficult to know what the 
specific research objectives were at the start of cohort 
recruitment, at the time of CRP measurement, or 
at the onset of the statistical analysis.”14 Only two 
studies reported the time elapsed between first lifetime 
presentation with coronary disease and assessment of 
CRP and this raised applicability concerns.
Step 5: meta-analysis
Meta-analysis of prognostic factor studies aims to 
summarise the (adjusted) prognostic effect of each 
factor of interest. In addition to missing estimates, 
challenges for the meta-analyst include (a) having 
different types of prognostic effect measures (eg, odds 
ratios and hazard ratios), which are not necessarily 
comparable30; (b) estimates without standard errors, 
which is a problem because meta-analysis methods 
typically weight each study by (a function of) their 
standard error; (c) estimates relating to various time 
points of the outcome occurrence or measurement; 
(d) different methods of measurement for prognostic 
factors and outcomes; (e) various sets of adjustment 
factors; and (f) different approaches to handling 
continuous prognostic factors (eg, categorisation, 
linear, non-linear trends), including the choice of 
cutpoint value when dichotomising continuous values 
into “high” and “normal” groups. Many of these issues 
lead to substantial heterogeneity and if a meta-analysis 
is performed, summary results cannot be directly 
interpreted.
Generally, meta-analysis results will be most 
interpretable, and therefore useful, when a separate 
meta-analysis is undertaken for groups of “similar” 
prognostic effect measures. In particular, we suggest 
considering a meta-analysis for:
• Hazard ratios, odds ratios, and risk ratios separately
•	Unadjusted and adjusted associations separately
•	Prognostic factor effects at distinct cutpoints (or groups 
of similar cutpoints) separately
•	Prognostic factor effects corresponding to a linear trend 
(association) separately
•	Prognostic factor effects corresponding to non-linear 
trends separately
•	Each method of measurement (for factors and 
outcomes) separately.
Ideally a meta-analysis of adjusted results should 
ensure that all included estimates are adjusted for the 
same set of other prognostic factors. This situation is 
unlikely and so a compromise could be to ensure that 
all adjusted estimates in the same meta-analysis have 
adjusted for at least a (predefined) minimum set of 
adjustment factors (that is, a core set of established 
prognostic factors).
Even when adhering to this guidance, unexplained 
heterogeneity is likely to remain because of other 
reasons (eg, differences in length of follow-up or in 
treatments received during follow-up). Therefore, if a 
meta-analysis is performed, a random effects approach 
is essential to allow for unexplained heterogeneity 
across studies (box 2), as previously described in The 
BMJ.53 This approach provides a summary estimate of 
the average prognostic effect of the index factor and 
the variability in effect across studies. Also potentially 
useful are meta-analysis methods to estimate the 
trend (eg, linear effect) of a prognostic factor that has 
been grouped into three or more categories within 
studies (with each category compared with the 
reference category). These methods generally model 
the estimated prognostic effect sizes in each category 
as a function of “exposure” level (eg, midpoint or 
median prognostic factor value in the category) and 
account for within-study correlation and between-
study heterogeneity.54-58 To apply these methods, 
some additional knowledge of the factor’s underlying 
distribution is usually needed to help define the 
“exposure” level because the chosen value can have an 
impact on the results.56
Application to CRP review
Hemingway and colleagues14 applied a random effects 
meta-analysis to combine 53 adjusted prognostic effect 
estimates for CRP from studies that adjusted for at least 
one of six conventional risk factors (age, sex, smoking 
status, diabetes, obesity, and lipids). The summary 
meta-analysis result was a risk ratio of 1.97 (95% 
confidence interval 1.78 to 2.17), which gives the 
average prognostic effect of CRP (for those in the top v 
bottom third of CRP distribution), and suggests larger 
CRP values are associated with higher risk. Although 
there was substantial between-study heterogeneity, 
nearly all estimates were in the same direction (that is, 
risk ratio >1). When restricting meta-analysis to just the 
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13 studies that adjusted for at least all six conventional 
prognostic factors, the summary risk ratio decreased to 
1.65 (95% confidence interval 1.39 to 1.96), and the 
between-study heterogeneity reduced. Using the study 
specific estimates given by Hemingway and colleagues, 
we updated this meta-analysis (fig 1), obtaining the 
same summary result but a wider confidence interval 
(1.34 to 2.04) through the Hartung-Knapp approach.16
Step 6: Quantifying and examining heterogeneity
For all meta-analyses, when there is large 
heterogeneity across included studies, it may be better 
not to synthesise the study results, but rather display 
the variability in estimates on a forest plot without 
showing an overall pooled estimate. When a meta-
analysis is performed in the face of heterogeneity, it 
is important to quantify and report the magnitude of 
heterogeneity itself; for example, through the estimate 
of (the between-study variance),62 or an approximate 
95% prediction interval indicating the potential true 
prognostic effect of a factor in a new population.53 63
Subgroup analyses and meta-regression can be used 
to examine or explore the causes of heterogeneity. A 
subgroup analysis performs a separate meta-analysis 
for categories defined by a particular characteristic, 
such as those with a low risk of bias, those with a 
follow-up of less than one year or of at least one year, 
or those set in countries in Europe. A better approach 
is meta-regression, which extends the meta-analysis 
equation shown in box 2 by including study level 
covariates,64 and allows a formal comparison of meta-
analysis results across groups defined by covariates 
(eg, low risk of bias studies v studies at higher risk 
of bias). Unfortunately, subgroup analyses and meta-
regression are often problematic. There will often be 
few studies per subgroup and low power to detect 
genuine causes of heterogeneity. Furthermore, study 
level confounding will be rife so that it is difficult to 
disentangle the associations for one covariate from 
another. For example, studies with a low risk of bias 
may also have a different length of follow-up or a 
particular cutpoint level compared with studies at 
higher risk of bias.
Application to CRP review
Hemingway and colleagues reported that meta-
regression identified four study level covariates that 
explained some between-study heterogeneity in the 
prognostic effect of CRP: definition of comparison 
group, number of adjustment factors, the (log) number 
of events, and the proportion of patients with stable 
coronary disease (reflecting study size).14 Studies 
originally reporting unequal CRP groups had stronger 
effects than those reporting CRP on a continuous scale. 
For each additional adjustment factor, the summary 
risk ratio decreased by 3%. The summary risk ratio 
was smaller among studies with more than the median 
number of outcome events, and smaller among studies 
confined to stable coronary disease. There was no 
evidence that the CRP effect differed according to the 
number of quality items reported by a study, or by the 
type of prognostic effect measure provided (that is, risk 
ratio, odds ratio, or hazard ratio).
Step 7: Examining small-study effects
The term “small-study effects” refers to when there is 
a systematic difference in prognostic effect estimates 
for small studies and large studies.65 A particular 
concern is when small studies (especially those 
that are exploratory because these often evaluate 
many potential prognostic factors with relatively few 
outcome events) show larger prognostic effects than 
larger studies. This difference may be due to chance or 
heterogeneity, but a major threat here is publication 
bias and selective reporting, which are endemic in 
prognosis research.36-38 Such reporting biases lead to 
smaller studies, with (statistically) significant or larger 
prognostic factor effect estimates being more likely to 
be published or reported in sufficient detail, and thus 
included in a meta-analysis, than smaller studies with 
non-significant or smaller prognostic effect estimates. 
This bias is a potential concern for unadjusted and 
adjusted prognostic effects. A primary study usually 
estimates an unadjusted prognostic effect for each of 
multiple prognostic factors, but study authors may 
only report effects that are statistically significant. In 
addition, adjusted results are often only reported for 
prognostic factors that retain statistical significance in 
univariable and multivariable analysis. A consequence 
is that meta-analysis results will be biased, with 
larger summary prognostic effects than in reality, and 
potentially some factors being deemed to have clinical 
value when actually they do not.
The evidence for small-study effects is usually 
considered on a funnel plot, which shows the study 
estimates (x axis) against their precision (y axis). A 
funnel plot is usually recommended if there are 10 
Box 2: Explanation of a random effects meta-analysis of prognostic factor  
effect estimates
The true prognostic effect of a factor is likely to vary from study to study; therefore 
assuming a common (fixed) prognostic effect is not sensible. If Yi and var(Yi) denote the 
prognostic effect estimate (eg, ln(hazard ratio), ln(odds ratio), ln(risk ratio), or mean 
difference) and its variance in study i, then a general random effects meta-analysis 
model can be specified as:
Yi ~N(μ,var(Yi)+τ
2).
Most researchers use either restricted maximum likelihood or the approach of 
DerSimonian and Laird to estimate this model,49 but other options are available, 
including a Bayesian approach.50 Of key interest is the estimate of μ, which reveals 
the summary (average) prognostic effect of the index prognostic factor of interest. The 
standard deviation of this prognostic factor effect across studies is denoted by τ, and 
non-zero values suggest there is between-study heterogeneity. Confidence intervals 
for µ should ideally account for uncertainty in estimated variances (in particular τ),51 
and we have found the approach of Hartung-Knapp to be robust for this purpose in 
most settings.16 52 When synthesising prognostic effects on the log scale, the summary 
results and confidence intervals require back transformation (using the exponential 
function) to the original scale.
Advanced multivariate meta-analysis methods are also available to handle multiple 
cutpoints,59 multiple methods of measurement,59 or different adjustment factors in 
prognostic factor studies.60 An introduction to multivariate meta-analysis has been 
published in The BMJ.61
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or more studies.65 The plot should ideally show a 
symmetric, funnel like shape, with results from larger 
studies at the centre of the funnel and smaller studies 
spanning out in both directions equally. Asymmetry 
will arise if there are small-study effects, with a 
greater proportion of smaller studies in one particular 
direction. Statistical tests for asymmetry in risk, odds 
and hazard ratios can be used, such as Peter’s and 
Debray’s test.66 67 Contour enhanced funnel plots also 
show the statistical significance of individual studies, 
and “missing” studies are perhaps more likely to fall 
within regions of non-significance if publication bias 
was the cause of small-study effects. An example is 
shown in figure 2.
As mentioned, small-study effects may also arise 
due to heterogeneity. Therefore, it is difficult to 
disentangle publication bias from heterogeneity in a 
single review. For example, if smaller studies used an 
analysis with fewer adjustment factors, then this may 
cause larger prognostic factor effects in such studies, 
rather than it being caused by publication bias. A 
multivariate meta-analysis could reduce the impact 
of small-study effects by “borrowing strength” from 
related information.61
A related concern is that smaller prognostic factor 
studies are generally at higher risk of bias than larger 
studies. Smaller studies tend to be more exploratory 
in nature and typically based on a convenient 
sample, often examining many (sometimes hundreds 
of) potential prognostic factors, with relatively 
few outcome events. This design leads to spurious 
(due to chance) and potentially biased (due to poor 
estimation properties68) prognostic effect estimates, 
which are more prone to selective reporting. In 
contrast, larger studies are often confirmatory studies 
focusing on one or a few prognostic factors, and are 
more likely to adopt a protocol driven and prospective 
approach, with clearer reporting regardless of their 
findings.3 Therefore, larger studies are less likely to 
identify spurious prognostic factor effect estimates. 
It is helpful to examine small-study effects (potential 
publication bias) when restricting analysis to the 
subset of studies at low risk of bias. If this approach 
resolves previous issues of small-study effects in the 
full meta-analysis, then it gives even more credence 
to focus conclusions and recommendations on the 
meta-analysis results based only on the higher quality 
studies.
Application to CRP review
Figure 2 shows a funnel plot of the study estimates 
from the CRP meta-analysis shown in figure 1. There is 
clear asymmetry, which shows the strong potential for 
publication bias. There was an insufficient number of 
studies considered at low risk of bias to evaluate small-
study effects in a subset of higher quality studies.
Step 8: reporting and interpretation of results
As with all research studies, clear and complete reporting 
is essential for reviews of prognostic factor studies. 
Most of the reporting guidelines of PRISMA (preferred 
reporting items for systemic reviews and meta-analyses) 
and MOOSE (meta-analysis of observational studies 
in epidemiology) will be relevant,69 70 and should be 
complemented by REMARK,47 48 which was aimed 
at primary prognostic factor studies. More specific 
guidance for reporting systematic reviews of prognostic 
factor studies is under development.
Interpretation and translation of summary meta-
analysis results is an important final step. The 
guidance in the previous steps is the essential input 
for this step. Discussion is necessary on whether and 
how the prognostic factors identified may be useful 
in practice (that is, translation of results to clinical 
practice), and what further research is necessary. 
Ideally impact studies (eg, randomised trials that 
compare groups which do and do not use a prognostic 
factor to inform clinical practice) are needed before 
strong recommendations for clinical practice are 
made; however, these studies are rare and outside the 
scope of the review framework outlined in this article.
To interpret the certainty (confidence) of the summary 
results of a review of intervention effectiveness, GRADE 
(grades of recommendation, assessment, development, 
and evaluation) was developed. This approach assesses 
the overall quality of and certainty in evidence for 
the summary estimates of the intervention effects by 
addressing five domains: risk of bias, inconsistency, 
imprecision, indirectness, and publication bias. The 
GRADE domains can be assessed using the information 
obtained by the tools and methods described in the 
above steps. However, it is not known whether these 
domains, developed for reviews of interventions, 
are equally applicable to assessing the certainty of 
summary results of systematic reviews of prognostic 
factor studies. Compared with reviews of intervention 
studies, allowing for heterogeneity (the inconsistency 
domain) might be more acceptable in reviews of 
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Fig 2 | Evidence of funnel plot asymmetry (small-study 
effects) in the C reactive protein meta-analysis shown 
in figure 1. The smaller studies (with higher standard 
errors) have risk ratio (RR) estimates mainly to the right 
of the larger studies, and therefore give the largest 
prognostic effect estimates. A concern is that this is due 
to publication bias, with “missing” studies potentially 
falling to the left side of the larger studies and in the 
lighter shaded regions denoting non-significant RR 
estimates
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prognostic factor studies because of the inevitable 
heterogeneity caused by study differences in methods 
of measurement, adjustment factors, and statistical 
analysis methods, among others. Furthermore, the 
threat of selective reporting or publication bias in 
reviews of prognostic factor studies may be more 
severe than in reviews of intervention studies because 
of the problems of exploratory studies, poor reporting, 
and biased analysis methods.
There is limited empirical evidence for using the 
existing domains to grade the certainty of summary 
estimates of prognostic factor studies, although a first 
attempt has been made71; in addition, an assessment 
has been performed on grading the certainty of evidence 
of summary estimates of overall prognosis studies.72 
Reviewers need to be especially cautious when 
comparing the adjusted prognostic value of multiple 
index factors, for example, to conclude whether the 
summary adjusted hazard ratio for prognostic factor A 
is larger than that for factor B. Usually different sets of 
studies will be available for each index factor, and so 
the comparison will be indirect and potentially biased. 
Moreover, the studies evaluating factor A may often 
have used different sets of adjustment factors (other 
prognostic factors) than those evaluating factor B. It 
will be rare to find studies on different index factors 
that used exactly the same set of adjustment factors. We 
therefore recommend reviewers restrict comparisons 
(of the adjusted prognostic value) of two or more index 
factors to those studies that at least used a similar, 
minimally required set of adjustment factors.73 Even 
then, due to different scales and distributions of each 
factor (eg, continuous or binary), a simple comparison 
of the prognostic effect sizes (eg, hazard ratio for factor 
A v hazard ratio for factor B) may not be straightforward.
Application to CRP review
The meta-analysis results suggest CRP is a prognostic 
factor for the risk of death and non-fatal cardiovascular 
events, even when only including the largest studies 
that adjusted for all six conventional prognostic 
factors. In their discussion, Hemingway and colleagues 
downgraded the meta-analysis findings because of a 
strong concern about the quality and reliability of the 
underlying evidence.14 The absence of prespecified 
protocols, poor and potentially biased reporting, 
and strong potential for publication bias prevented 
the authors from making firm conclusions about 
whether CRP has prognostic value after adjustment 
for established prognostic factors. They state that 
the concerns “explicitly challenge the statement for 
healthcare professionals made by the Centers for 
Disease Control that measuring CRP is both ‘useful’ 
and ‘independent’ as a marker of prognosis.”74
Summary
In this article, we described the key steps and methods 
for conducting a systematic review and meta-analysis 
of prognostic factor studies. Current reviews are often 
limited by the quality and heterogeneity of primary 
studies.75 76 We expect the prevalence of such reviews 
to grow rapidly, especially as Cochrane has recently 
embarked on prognosis reviews (see also the Cochrane 
Prognosis Methods Group website www.methods.
cochrane.org/prognosis).77 Our guidance will help 
researchers to write grant applications for reviews of 
prognostic factor studies, and to develop protocols 
and conduct such reviews. Protocols of prognostic 
factor reviews should be published ideally at the same 
time as the review is registered, for example within 
PROSPERO, the international prospective register of 
systematic reviews (www.crd.york.ac.uk/PROSPERO/), 
or the Cochrane database.77 Our guidance will also 
allow readers and healthcare providers to better judge 
reports of prognostic factor reviews. 
Finally, we note that some of the limitations described 
(eg, use of different cutpoint values across studies) 
could be alleviated if the individual participant data 
were obtained from primary prognostic factor studies78 
rather than being extracted from study publications; 
although, this may not solve all problems (eg, quality 
of original study, availability of different adjustment 
factors).79 Further discussion on individual participant 
data meta-analysis of prognostic factor studies is given 
elsewhere.80
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